Clinical Trials Browser

Phase 1 × Completed × Rogaratinib × Clear all

NCT03473756 2025-04-09

FORT-2

Phase 1 Completed

37 enrolled 15 charts

Urinary Bladder Neoplasms, Carcinoma, Transitional Cell

NCT01976741 2021-05-06

Dose Escalation Pan-FGFR (Fibroblast Growth Factor Receptor) Inhibitor (Rogaratinib)

Phase 1 Completed

168 enrolled 59 charts

GenitourinaryHead & NeckThoracic

Adenocarcinoma of Lung, Urinary Bladder Neoplasms, Head and Neck Neoplasms, Neoplasm Metastasis, Neoplasms

NCT03788603 2021-03-29

Rogaratinib (BAY1163877) in Chinese Patients

Phase 1 Completed

Neoplasms

NCT02592785 2018-04-18

Phase I Dose Escalation Study of BAY 1163877 (Rogaratinib) in Japanese Subjects With Refractory, Locally Advanced or Metastatic Solid Tumors

Phase 1 Completed

Neoplasms